Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 93

Sort by

Sort Order Select

Journal Articles

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Blood (2025) 146 (22): 2629–2640.

https://doi.org/10.1182/blood.2025029909

Published: 2025

Includes: Supplemental data

Journal Articles

Novel immune gene expression signature risk-stratifies Mantle Cell Lymphoma outcomes independent of TP53 status

Blood (2025) 146 (Supplement 1): 352.

https://doi.org/10.1182/blood-2025-352

Published: 2025

Journal Articles

Folate receptor beta targeting of tumor-associated macrophages improves lymphoma cell responses to CD19 CAR T cells

Kerttu Kalander, Katri Oksa, Selma Sorri, Suvi-Katri Leivonen, Päivi Ojala, Sirpa Leppä

Blood (2025) 146 (Supplement 1): 5891.

https://doi.org/10.1182/blood-2025-5891

Published: 2025

Journal Articles

Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders

Leonardo P. A. Biral, Veronica S. Russell, Chee Leong Cheng, Andrew Evans, Sirpa Leppä, Sarah Ondrejka, Payal Sojitra, Catalina Amador, Jean Koff, Cassandra Love, Jennifer Shingleton, Clayton Parker, Emily F. Mason, Raju Pillai, Yuri Fedoriw, Sandeep Dave, Jie Wang

Blood (2025) 146 (Supplement 1): 1747.

https://doi.org/10.1182/blood-2025-1747

Published: 2025

Journal Articles

Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy

Selma Sorri, Katri Oksa, Kerttu Kalander, Päivi Ojala, Sirpa Leppä

Blood (2025) 146 (Supplement 1): 2342.

https://doi.org/10.1182/blood-2025-2342

Published: 2025

Journal Articles

Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Paul J. Bröckelmann, Boris Böll, Daniel Molin, Gundolf Schneider, Sirpa Leppä, Julia Meissner, Peter Kamper, Martin Hutchings, Jacob Haaber Christensen, Ulf Schnetzke, Michael Fuchs, Dennis A Eichenauer, Bastian von Tresckow, Helen Kaul, Peter Borchmann, Alexander Fossa

Blood (2024) 144 (Supplement 1): 3054.

https://doi.org/10.1182/blood-2024-202120

Published: 2024

Journal Articles

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Blood (2024) 144 (Supplement 1): 240.

https://doi.org/10.1182/blood-2024-200735

Published: 2024

Journal Articles

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Blood (2024) 144 (Supplement 1): 237.

https://doi.org/10.1182/blood-2024-201441

Published: 2024

Journal Articles

Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Miro Nylén, Leo Meriranta, Emil Hiitola, Maare Arffman, Harald Holte, Judit Mészáros Joergensen, Peter Brown, Sirkku Jyrkkiö, Mats Jerkeman, Øystein Fluge, Magnus Björkholm, Lars Møller Pedersen, Mikael Eriksson, Satu Mustjoki, Sirpa Leppä, Mikko Myllymäki

Blood (2024) 144 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2024-201928

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Blood (2024) 144 (Supplement 1): 342.

https://doi.org/10.1182/blood-2024-200262

Published: 2024

Journal Articles

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Blood (2023) 142 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2023-179887

Published: 2023

Journal Articles

Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas

Maare Arffman, Leo Meriranta, Judit Mészáros Jørgensen, Harald Holte, Øystein Fluge, Peter de Nully Brown, Kristina Drott, Sirkku Jyrkkiö, Suvi-Katri Leivonen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2023-177849

Published: 2023

Journal Articles

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Lorenzo Falchi, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Emmanuel Bachy, Guillaume Cartron, Cyrus Khan, Monica Tani, Joaquin Martinez-Lopez, Nancy L. Bartlett, Antonio Salar, Joshua Brody, Sirpa Leppä, Aurelien Berthier, Martine Kallemeijn, James Relf, Saibah Chohan, Linda Lundberg, Martin Hutchings

Blood (2023) 142 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2023-173949

Published: 2023

Journal Articles

Unraveling the Role and Spatial Architecture of Cancer-Associated Fibroblasts in Classical Hodgkin Lymphoma

Suvi-Katri Leivonen, Kristiina Karihtala, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 4386.

https://doi.org/10.1182/blood-2023-173117

Published: 2023

Journal Articles

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Leo Meriranta, Maare Arffman, Judit Mészáros Jørgensen, Harald Holte, Kristina Drott, Henrikki Almusa, Emma Saarinen, Sari Hannula, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Ølgod Pedersen, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 1625.

https://doi.org/10.1182/blood-2023-188493

Published: 2023

Journal Articles

Reduced Immune-Cell Infiltration in MHC Class I Negative DLBCL

Kanutte Huse, Yngvild Blaker, Jillian Frances Wise, Ankush Sharma, Leo Meriranta, Kathrine Thuestad Isaksen, Ivana Spasevska, Sigve Nakken, Vera Hilden, Mette Førsund, Sirpa Leppä, Erlend B. Smeland, Harald Holte, June Helen Myklebust

Blood (2023) 142 (Supplement 1): 179.

https://doi.org/10.1182/blood-2023-189098

Published: 2023

Journal Articles

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Blood (2023) 142 (Supplement 1): 433.

https://doi.org/10.1182/blood-2023-173951

Published: 2023

Journal Articles

Clinical Impact of the Spatial Organization of the Immune Tumor Microenvironment in Diffuse Large B-Cell Lymphoma

Matias Autio, Suvi-Katri Leivonen, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppä

Blood (2023) 142 (Supplement 1): 178.

https://doi.org/10.1182/blood-2023-177893

Published: 2023

Journal Articles

Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression

Blood (2023) 142 (Supplement 1): 176.

https://doi.org/10.1182/blood-2023-182294

Published: 2023

Journal Articles

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Maare Arffman, Leo Meriranta, Harald Holte, Judit Jørgensen, Peter De Nully Brown, Sirkku Jyrkkio, Mats Jerkeman, Øystein Fluge, Magnus Björkholm, Matias Autio, Suvi-Katri Leivonen, Sirpa Leppa

Blood (2022) 140 (Supplement 1): 1316–1317.

https://doi.org/10.1182/blood-2022-158426

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fixed-duration epcoritamab plus R 2 drives favorable outcomes in relapsed or refractory follicular lymphoma

Novel immune gene expression signature risk-stratifies Mantle Cell Lymphoma outcomes independent of TP53 status

Folate receptor beta targeting of tumor-associated macrophages improves lymphoma cell responses to CD19 CAR T cells

Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders

Immune landscape characterization of relapsed/refractory B-cell lymphoma patients treated with CD19 CAR-T cell therapy

Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project

Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion Cohort

Joint Analyses of Serum Proteins and Circulating Tumor DNA Improves Risk Assessment and Subtype Stratification in Large B-Cell Lymphomas

Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Unraveling the Role and Spatial Architecture of Cancer-Associated Fibroblasts in Classical Hodgkin Lymphoma

Distinct Genetic and Fragmentomic Signatures of Plasma Ctdna Synergize and Resolve Clinical Challenges in Patients with Large B-Cell Lymphoma

Reduced Immune-Cell Infiltration in MHC Class I Negative DLBCL

Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume

Clinical Impact of the Spatial Organization of the Immune Tumor Microenvironment in Diffuse Large B-Cell Lymphoma

Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression

Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only